Verisk Analytics, Inc. (VRSK) Down 4.5% — Should I Convert Back to Cash?
Verisk Analytics, Inc. (VRSK) closed sharply lower this Monday, shedding $8.67 to finish at $183.15 on the NASDAQ. The 4.52% decline adds meaningful pressure to an already-challenged chart: shares now sit roughly 33.7% below their 52-week high of $276.19, reached on August 20, 2025, and are trading far closer to the 52-week low of $155.94 than to any recent peak. For investors who have held through the extended drawdown, Monday's move does little to build confidence in a near-term recovery.
Volume for the session came in at approximately 591,000 shares, a fraction of the 90-day average of roughly 2.21 million. That unusually light turnover stands out given the magnitude of the price decline—sellers were able to push VRSK down more than 4% without any corresponding surge in participation, suggesting the move reflected repositioning rather than broad-based capitulation.
Why Verisk Analytics, Inc. Price is Moving Lower
The dominant catalyst behind today's selloff was a Delaware court ruling that revived Verisk's previously terminated $2.35 billion cash acquisition of AccuLynx, a roofing-software company. On August 7, 2026, Delaware Vice Chancellor Bonnie David ruled that Verisk's December 26, 2025 termination of the deal was invalid, finding that Verisk's own willful conduct contributed to the Federal Trade Commission's extended antitrust review. The court ordered Verisk to use commercially reasonable efforts to obtain FTC clearance and close the acquisition if regulators approve it—effectively forcing the company back to a transaction it had walked away from. Verisk was also ordered to pay AccuLynx's $3.85 million in direct costs plus prejudgment interest.
The market's reaction reflects a clear-eyed assessment of the risks the ruling reintroduces. Verisk now faces renewed execution risk tied to FTC approval, the prospect of funding a large acquisition it had already moved on from, and the uncertainty of integrating a software business in an environment where deal timelines remain unpredictable. These are not abstract concerns—a $2.35 billion outlay represents a material use of capital for a company with a market cap just under $25 billion, and the reinstatement of that obligation arrives without any of the strategic optionality Verisk would have had if it had pursued the deal on its own terms. Reuters noted that the transaction remains contingent on FTC approval, leaving investors in the uncomfortable position of pricing an uncertain outcome.
The earnings backdrop, while not the direct trigger on Monday, adds important context. Verisk reported adjusted EPS of $1.98 against a $1.93 consensus estimate—a $0.05 beat—and revenue of $806.30 million versus $804.02 million expected, on July 29, 2026. Revenue rose 4.3% year over year and adjusted EPS improved 5.3% from $1.88 in the prior-year period. On the surface, those are constructive numbers, and management reaffirmed 2026 revenue guidance of $3.19 billion to $3.24 billion. But GAAP EPS fell 3.3% to $1.75 and net income declined 9.8% to $228.6 million, a divergence that complicates the narrative and gives investors reason to look past the headline beats. Against that mixed fundamental backdrop, the Delaware ruling arrives at a particularly inopportune moment—layering deal-related uncertainty onto a business already navigating a GAAP earnings contraction.
What is the Verisk Analytics, Inc. Rating - Should I Sell?
Weiss Ratings assigns VRSK a D+ rating. The rating was downgraded on 7/31/2026. Current recommendation is Sell.
There are genuine operational strengths embedded in Verisk's business. Revenue growth of 4.36% and a 28.23% profit margin together support both the Excellent Growth Index and the Excellent Efficiency Index—the latter particularly striking for an analytics and data platform serving the insurance industry, where recurring-revenue models and proprietary data assets translate directly into durable margin profiles. The Good Solvency Index rounds out the balance sheet picture, indicating that Verisk carries manageable leverage under normal operating conditions. These are real positives, and they prevent the D+ rating from reflecting an across-the-board deterioration in business quality.
The drag on the overall rating comes from two areas that carry significant weight for performance-oriented investors. The Weak Total Return Index is a pointed signal: despite the operational strengths above, shareholders have not been well rewarded over time, a dynamic that the stock's roughly 33.7% drawdown from its 52-week high illustrates in concrete terms. The Weak Volatility Index compounds this concern—VRSK has demonstrated a tendency to move sharply and unpredictably, which raises the risk profile for investors who cannot absorb wide price swings. Monday's 4.52% single-session decline on light volume is a live example of that volatility characteristic in action.
Within the Industrials sector, Verisk is in line with Thomson Reuters Corporation (TRI, D+), Copart, Inc. (CPRT, D+), Equifax Inc. (EFX, D+), and Booz Allen Hamilton Holding Corporation (BAH, D+)—a peer group that collectively reflects broader headwinds across data, professional services, and analytics names. GFL Environmental Inc. (GFL, D) trails the group, but VRSK's forward P/E of 29.48 makes it one of the more richly valued names in this company, demanding consistent execution at a moment when deal uncertainty has just been reintroduced.
About Verisk Analytics, Inc.
Verisk Analytics, Inc. (VRSK) is an Industrials company headquartered in Jersey City, New Jersey and founded in 1971. The company's core business is providing data analytics and technology solutions to the insurance industry across both domestic and international markets. Its underwriting solutions encompass policy language, prospective loss costs, rating rules, and risk segmentation tools that insurers rely on to price policies and manage exposure—services that sit at the foundation of the U.S. property and casualty market's pricing infrastructure. Catastrophe modeling, life insurance workflow solutions, and specialty business management for insurance and reinsurance operations round out the underwriting side of its portfolio.
On the claims side, Verisk provides property estimating platforms used by professionals assessing building repair and reconstruction costs, anti-fraud detection tools for property and casualty insurers, casualty claims decision and workflow automation products, and international claims solutions covering personal injury and motor insurance franchises. This dual focus on underwriting and claims gives Verisk a presence across the full insurance lifecycle, making it a deeply embedded vendor for carriers that rely on its platforms for day-to-day operational decisions rather than as an ancillary service.
Verisk's competitive moat rests on several difficult-to-replicate advantages: decades of proprietary loss data accumulated through industry participation, an extensive intellectual property portfolio, and deeply integrated software workflows that create meaningful switching costs for insurance customers. Its international operations extend this model beyond U.S. borders, providing diversified exposure to insurance markets with varying growth profiles. These structural advantages have historically supported the company's strong margin profile, though they are currently being weighed against the strategic and financial uncertainties introduced by the reinstated AccuLynx acquisition process.
Investor Outlook
Verisk Analytics, Inc. (VRSK) carries a Weiss Rating of D+ (Sell), and Monday's sharp decline on the Delaware court ruling underscores the near-term risks that justify that cautious stance. Investors should monitor FTC developments around the AccuLynx acquisition closely—any signal of regulatory approval or renewed dealmaking costs will likely drive further price movement—while keeping an eye on whether the GAAP earnings contraction in the most recent quarter proves transitory or widens further. See full rankings of all D+-rated Industrials stocks inside the Weiss Stock Screener.
--